Physician profile
Michael L Quinlan
NPI 1134122906
$499.35
in general payments reported to CMS, 2019-2025
14 companies · $13.56 in 2025
The $13.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2022: $16.00 · 2023: $269 · 2024: $78.89 · 2025: $13.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $121.68 | 2019 | |
| Amgen INC. | $64.74 | 2023-2024 | Prolia, Evenity, Repatha |
| Otsuka America Pharmaceutical, INC. | $62.65 | 2023-2024 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $59.71 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $30.59 | 2023-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $29.97 | 2023 | |
| Dexcom, INC. | $23.20 | 2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $18.92 | 2023 | Tymlos |
| Glaxosmithkline, LLC. | $18.70 | 2023 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $16.00 | 2022 | |
| Novo Nordisk INC | $14.06 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $13.60 | 2023 | |
| Abbott Laboratories | $12.82 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $12.71 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Quinlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.